Literature DB >> 23845539

The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.

Katja Zerjavic1, Boris Zagradisnik, Lidija Lokar, Marjana G Krasevac, Nadja K Vokac.   

Abstract

BACKGROUND: The inherited JAK2 46/1 haplotype is strongly associated with the development of myeloproliferative neoplasms (MPNs), and its increased frequency has also been reported in splanchnic venous thrombosis (SVT). In the present study, the role of the JAK2 46/1 haplotype in non-splanchnic venous thrombosis (non-SVT) was investigated. METHODS AND
RESULTS: We genotyped 438 patients with non-SVT, 226 patients with MPNs and 459 healthy controls for three single nucleotide polymorphisms (SNPs) which tag the JAK2 46/1 haplotype (rs12342421 G>C, rs12343867 T>C and rs10974944 C>G). We found statistically significant association of the rs12342421 GC+CC genotypes (OR=1.40; p=0.023) and the rs12343867 TC+CC genotypes (OR=1.83; p=7.02 x 10(-5)) with non-SVT. We also found that the CC haplotype of these two SNPs was associated with an increased risk of the disease (OR=1.68; p=0.009). Stratification analysis indicated that the observed association of the JAK2 46/1 haplotype with non-SVT was probably largely free of confounding effect of thrombophilic risk factors. In addition, we established a strong association of SNPs rs12342421 and rs10974944 and their CG haplotype with MPNs and with JAK2 V617F-positive MPNs.
CONCLUSIONS: This study provides statistical evidence that SNPs rs12342421 and rs12343867 are associated with an increased risk of non-SVT. Consistently, haplotypes of the SNPs were also associated with non-SVT risk, suggesting that inherited genetic variation in the JAK2 gene may play a role in the pathogenesis of non-SVT. Furthermore, the reported associations of the JAK2 46/1 haplotype with MPNs as well as with the occurrence of the JAK2 V617F mutation in MPNs were confirmed.
© 2013.

Entities:  

Keywords:  AS-PCR; Association study; CI; ET; FDR; HWE; Hardy-Weinberg equilibrium; JAK2; JAK2 46/1 haplotype; JAK2 V617F mutation; Janus kinase 2; MPNs; Myeloproliferative neoplasms; Non-splanchnic venous thrombosis; OR; PMF; PV; SNP; SVT; allele-specific polymerase chain reaction; confidential interval; essential thrombocythaemia; false discovery rate; myeloproliferative neoplasms; non-SVT; non-splanchnic venous thrombosis; odds ratio; polycythaemia vera; primary myelofibrosis; single nucleotide polymorphism; splanchnic venous thrombosis

Mesh:

Substances:

Year:  2013        PMID: 23845539     DOI: 10.1016/j.thromres.2013.06.021

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Authors:  Su Pin Koh; Shea Ping Yip; Kwok Kuen Lee; Chi Chung Chan; Sze Man Lau; Chi Shan Kho; Chi Kuen Lau; Shek Ying Lin; Yat Ming Lau; Lap Gate Wong; Ka Leung Au; Kit Fai Wong; Raymond W Chu; Pui Hung Yu; Eudora Y D Chow; Kate F S Leung; Wai Chiu Tsoi; Benjamin Y M Yung
Journal:  BMC Genet       Date:  2014-12-20       Impact factor: 2.797

2.  JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.

Authors:  Nguyen Thy Ngoc; Bui Bich Hau; Nguyen Ba Vuong; Nguyen Thi Xuan
Journal:  Mol Genet Genomic Med       Date:  2022-08-22       Impact factor: 2.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.